A randomized controlled experimental study from Columbia Medicine published in JAHA show that ANGER😡impairs endothelial cells health =>blood vessel dilation impaired =>atherosclerosis

ahajournals.org/doi/full/10.11…

American Heart Association Daichi Shimbo MD

Life is too short to be angry!

🔘In this retrospective study
No increase in renal or non-renal immune-related side effects with immunotherapy in patients with stage 4-5 CKD (eGFR<30), which is usually the exclusion criterion in clinical trials
The Oncologist OncoAlert #MedTwitter ASCO
doi.org/10.1093/oncolo…

95% of Advanced Prostate Cancer Consensus Conference Panellists DO NOT recommend ARPI switch for mCRPC. Yet why do investigators (many of them Panellists) and FDA approve this as control arm for trials?? “Unethical” says ONCODOC from the floor, as did Vinay Prasad MD MPH on GU Cast GU Cast | Urology podcast! #APCCC24

For patients on treatment with 177Lu-PSMA, the preferred imaging modality for response monitoring, as voted, is PSMA PET plus diagnostic CT (with iv iodine contrast), receiving 41% of the votes. There is no clear consensus!

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin

Many thanks and congratulations to silke gillessen and aurelius omlin and the superb #APCCC24 team on another spectacularly successful meeting! A clear consensus (unanimously) a great success 😀

A significant 80% of respondents report that genetic evaluation (germline and/or somatic) does influence their decision-making for the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) when testing is available without restrictions outside of a

A significant majority of respondents, 76%, do not let genetic evaluation results influence their first-line treatment decisions for metastatic hormone-sensitive prostate cancer (mHSPC) outside clinical trials, provided that testing is unrestricted.

#APCCC24 Advanced Prostate Cancer Consensus Conference

Most respondents favor both germline and somatic testing for patients with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of findings in somatic testing.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C

The majority of responses indicate a preference for both germline and somatic genetic testing in patients with metastatic castration-resistant prostate cancer (mCRPC), which is done regardless of somatic findings.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert

Who should receive chemotherapy before PSMA radioligand therapy?
Clinically very relevant question!
M.R.Smith

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Simon C Nick James GU Cast | Urology podcast! LARVOL Renu Eapen Emre Yekedüz Irbaz Riaz MD,MS,MBI,PhD Deborah Mukherji

No consensus on the necessity of genetic evaluation for high-risk localized prostate cancer among experts?

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Elena Castro Simon C Stacy Loeb, MD Nick James Christopher Sweeney, MBBS GU Cast | Urology podcast! Joaquin Mateo LARVOL

Dosing of radioligand therapy in special situations and/or toxicity! L. Emmett
⭕️ Heterogeneity predicts toxicity and response!
⭕️Less data about delayed toxicity
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Simon C Nick James GU Cast | Urology podcast!

PSMA PET selection of patients
Thomas Hope
☢️ Baseline PSMA relates response
☢️ Patients for PSMA RLT should be selected based on uptake greater than liver!
☢️ Repeat imaging (preferably with post-treatment (SPECT) should be performed to evaluate PSMA uptake
#APCCC24

What do you need to know about the PREDICT-RT study for high-risk #prostatecancer - Paul Nguyen discusses the details of the trials. FULL VIDEO: youtube.com/watch?v=2wSAuI… Dana-Farber Brigham and Women's Hospital #pcsm

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 How to monitor and manage toxicities with Lutetium-177 PSMA RLT? #LuisEmmett 👉adaptive dosing based on SPECT scan results may improve toxicity, & rule out disease progression before assuming marrow toxicity👇OncoAlert PCF Science

Ana Aparicio How do non-DDR genomic alterations influence management of patients with advanced prostate cancer?🧬🩸
⭕️ Prospective marker-selected or marker-stratified studies to validate the predictive value of other non-HRD genomic alterations are needed.

#APCCC24

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 most panelists favor continuing Lutetium-177 RLT Rx to complete 6 cycles even after PSA/clinical/radiological response after 4 cycles in mCRPC #prostatecancer OncoAlert PCF Science silke gillessen

Advanced Prostate Cancer Consensus Conference OncoAlert PCF Science silke gillessen #APCCC24 Advanced Prostate Cancer Consensus Conference 👉 majority of panelists favored retreating pts with mCRPC #prostatecancer with lutetium-177 RLT Rx if they had response to previous Lutetium-177 Rx lasting for more than 6 months OncoAlert PCF Science

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 brilliant talk by Michael Hofman 👉Current gallium and fluorinated PSMA diagnostic tracers are equivalent & current PSMA radiologist therapies (PSMA-617 & PSMA I&T)seem radio-equivalent👇OncoAlert PCF Science silke gillessen

🎯 what about aggressive variant PCa ? >> molecular profiling information to better define this subset of pts! 👇 OncoAlert Advanced Prostate Cancer Consensus Conference Yüksel Ürün UroToday.com CLOC: Curso Latinoamericano de Oncología Clínica